Prophylactic and therapeutic composition for circulatory disorders and method of treatment

A prophylactic and therapeutic agent for circulatory disorders, comprising a pyrazolone derivative of the formula: ##STR1## wherein R.sub.1 represents a hydrogen atom, an aryl group, an alkyl group having 1 to 5 carbon atoms or an alkoxycarbonylalkyl group having a total carbon number of 3 to 6; R.sub.2 represents a hydrogen atom, an aryloxy group, an arylmercapto group, an alkyl group having 1 to 5 carbon atoms or hydroxyalkyl group having 1 to 3 carbon atoms or R.sub.1 and R.sub.2 taken together represent an alkylene group having 3 to 5 carbon atoms; R.sub.3 represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, a cycloalkyl group having 5 to 7 carbon atoms, a hydroxyalkyl group having 1 to 3 carbon atoms, a benzyl group, a naphthyl group, or a phenyl group which is unsubstituted or substituted with 1 to 3 substituents which are the same or different selected from the group consisting of alkyl groups having 1 to 5 carbon atoms, alkoxy groups having 1 to 5 carbon atoms, hydroxyalkyl groups having 1 to 3 carbon atoms, alkoxycarbonyl groups having total carbon number of 2 to 5, alkylmercapto groups having 1 to 3 carbon atoms, alkylamino groups having 1 to 4 carbon atoms, dialkylamino groups having total carbon number of 2 to 8, halogen atoms, trifluoromethyl group, carboxyl group, cyano group, hydroxyl group, nitro group, amino group and acetamide group, or a pharmaceutically acceptable salt thereof as an active ingredient. The agent of the present invention is useful as a prophylactic and therapeutic agent for circulatory disorders, particularly as an inhibitor against lipid peroxidation and/or an agent for normalizing cerebral dysfunctions.

Skip to:  ·  Claims  ·  References Cited  · Patent History  ·  Patent History

Claims

Referenced Cited
U.S. Patent Documents
3514465 May 1970 Posselt et al.
3658845 April 1972 Posselt et al.
3781439 December 1973 Zoni et al.
4000294 December 28, 1976 Moller et al.
4005215 January 25, 1977 Moller et al.
4053621 October 11, 1977 Moller et al.
4112227 September 5, 1978 Moller et al.
4288446 September 8, 1981 Moller et al.
4670460 June 2, 1987 Mardin et al.
4698344 October 6, 1987 Sasse
Foreign Patent Documents
0126651 November 1984 EPX
2836891 March 1980 DEX
47-47734 August 1972 JPX
47-29900 August 1972 JPX
51-13766 February 1976 JPX
52-77088 June 1977 JPX
59-512 January 1984 JPX
59-141517 August 1984 JPX
59-175469 October 1984 JPX
Other references
  • Failure of Nafazatrom to Reduce Infarct Size and Arrhythmias in a Porcine Model of Acute Coronary Occlusion, V.B. Fiedler, European J. of Pharmac. 114 (1985) 189-195. Microsomal N-Hydroxylation of Trans 4'-Alkoxy-4-Acetamidostilbenes, R.E. Gammans, et al. Drug Metabolism and Disposition vol. 6, No. 3., 226-231 (1983). Chem. Abst. 73:45404h, (1970) Williams et al. Chem. Abst. 101:222712(b), (1984) Mardin et al. Chem. Abst. 102:17649r. (1985) Moeller et al. Chem Abstracts 102:56154v. (1985)--Bayer, A.G. "Stroke" vol. 8, No. 1, Jan.-Feb. 1977 pp. 51-57. Cardiovascular Research 14. (1980):pp. 371-395.
Patent History
Patent number: RE35801
Type: Grant
Filed: Sep 20, 1994
Date of Patent: May 19, 1998
Assignee: Mitsubishi Chemical Corporation (Tokyo)
Inventors: Hiroyoshi Nishi (Meerbusch), Toshiaki Watanabe (Yokohama), Satoshi Yuki (Machida), Yasuhiro Morinaka (Tsuchiura), Katsuhiko Iseki (Tsukuba), Hiroko Nakajima (nee Sakurai) (Tokyo)
Primary Examiner: Kevin E. Weddington
Attorneys: David G. Conlin, George W. Neuner
Application Number: 8/309,558